IMR Press / FBL / Volume 11 / Issue 3 / DOI: 10.2741/1973

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Angiogenic switch in Barrett's adenocarcinoma: the role of vascular endothelial growth factor
Show Less
1 Department of Zoology, K.C. College, Hetampur, Birbhum, West Bengal, India
2 Cancer Research Unit, VA Medical Center, Kansas City, MO and Division of Hematology and Oncology, Department of Medicine, University of Kansas Medical Center, Kansas City, Kansas
3 St John’s Clinic, Gastroenterology, Springfield, MO
Academic Editor:Sushanta K. Banerjee
Front. Biosci. (Landmark Ed) 2006, 11(3), 2336–2348;
Published: 1 September 2006
(This article belongs to the Special Issue Growth factors and cancer)

The development of cancerous cells from the normal cells is the consequence of multiple genetic and epigenetic abuses. Activation of "Angiogenic switch" or formation of new blood vessels is one of the upshots of these abuses. Multiple factors are associated with the activation of angiogenic switch. Vascular endothelial growth factor (VEGF) and its down stream signaling molecules is important troupe of this event. In this article, we reviewed the role this troupe in the development of Barrett's adenocarcinoma and also discussed the possible remedies, which have the impact on blocking the function of this troupe.

anti-angiogenic therapy
Barrett’s esophagus
Barrett’s adenocarcinoma
Vascular Endothelial Growth Factor
Back to top